Dr. Elena Castro on Advancing mHSPC Treatment

Dr. Elena Castro talks about the evolving treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), focusing on early treatment intensification strategies. She discusses the heterogeneity of mHSPC, highlighting the consistent benefits of combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and docetaxel by reviewing key clinical trial data, including ARASENS and PEACE-1. Additionally, several case studies on mHSPC patients were presented by Dr Krishna Chaitanya, Dr Poulami Basu, and Dr. Sanyo Dsouza.